<DOC>
	<DOCNO>NCT02659735</DOCNO>
	<brief_summary>The purpose study compare rate extent absorption JNJ-63623872 follow administration single dose three different concept formulation follow administration current formulation , feed fasted condition , healthy adult participant .</brief_summary>
	<brief_title>A Study Assess Relative Oral Bioavailability JNJ-63623872 Administered Oral Concept Formulations Compared Current Tablet Formulation</brief_title>
	<detailed_description>This Phase 1 , open-label , 2-panel , randomize , crossover study healthy adult participant assess relative bioavailability JNJ-63623872 . The study population consist 48 healthy adult participant , equally divide 2 panel : 24 participant Panel 1 24 participant Panel 2. participant randomize within panel . Participants randomized panel . Panels 1 2 perform sequentially . Participants participate one panel also participate panel . In Panel 1 , 4 subsequent treatment session ( Periods I , II , III IV ) , participant receive 4 treatment ( Treatments A , B , C , D ) , randomize accord classical 4 sequence , 4 period Williams design . In Panel 2 , 3 subsequent treatment session ( Periods I , II III ) , participant receive 3 treatment ( Treatments E , F , G ) randomize accord classical 6 sequence , 3 period Williams design . Primarily , pharmacokinetic parameter evaluate . Participants ' safety monitor throughout study .</detailed_description>
	<criteria>A female participant must either : ) Not childbearing potential : postmenopausal great ( &gt; ) 45 year age amenorrhea least 2 year , age amenorrhea least 6 month serum follicle stimulate hormone ( FSH ) level &gt; 40 international Unit/Liter ( IU/L ) ; OR b ) Permanently sterilize ( example , bilateral tubal occlusion [ include tubal ligation procedure consistent local regulation ] , hysterectomy , bilateral salpingectomy , bilateral oophorectomy ) otherwise incapable become pregnant ; OR c ) If childbearing potential heterosexually active , practice effective method contraception entry agree continue use two effective method contraception throughout study least 90 day receive last dose study drug A female participant ( except postmenopausal ) must negative serum beta human chorionic gonadotropin ( beta hCG ) pregnancy test Screening Day 1 Participants must Body Mass Index ( BMI ) 18.0 30.0 kilogram per meter^2 ( kg/m^2 ) ( extremes include ) Participants must blood pressure ( participant supine least 5 minute ) 90 140 millimeter mercury ( mmHg ) systolic , inclusive , high 90 mmHg diastolic Screening Participants must nonsmoker least 3 month prior Screening Participant history current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , hepatic renal insufficiency , thyroid disease , neurologic psychiatric disease , infection , illness Investigator considers exclude participant could interfere interpretation study result Participant past history heart arrhythmia ( extrasystoli , tachycardia rest ) , history risk factor Torsade de Pointes syndrome ( example , hypokalemia , family history long QT Syndrome ) Participant history clinically significant skin disease , limited , dermatitis , eczema , drug rash , psoriasis , food allergy , urticaria Participant history clinically significant drug allergy , limited , sulfonamides penicillin , drug allergy diagnose previous study experimental drug Participant take disallow therapy plan first intake study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Influenza A virus</keyword>
	<keyword>JNJ-63623872</keyword>
	<keyword>Healthy</keyword>
</DOC>